Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
29 juil. 2024 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22 juil. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis will host a KOL virtual event July 29, 2024
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
09 juil. 2024 16h53 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis
Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals
02 juil. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, July 02, 2024 (GLOBE NEWSWIRE) -- Atopic Dermatitis Market to Register Incremental Growth by 2034, Examines DelveInsight | Key Companies - Arcutis Biotherapeutics, Amgen, Kyowa Kirin,...
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
10 juin 2024 14h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15%.
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
05 juin 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago June 8-10.
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
28 mai 2024 07h35 HE
|
Numab Therapeutics AG
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08 mai 2024 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to...
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
07 mai 2024 04h09 HE
|
AKAMPION
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
29 avr. 2024 04h00 HE
|
AKAMPION
si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...